, June 5, 2014
/PRNewswire/ -- CerMed is pleased to announce its new corporate name OncoGenesis. According to Founder and Board Chairman Peter Gombrich
, "The name OncoGenesis better articulates our broader focus beyond point-of-care cervical cancer screening, to include cancer diagnostics and personalized directed therapeutics. We have made great progress over the past year demonstrating the efficacy of our CerMark multiplexed biomarkers which were previously proven on histology samples and now with cytological patient samples. This point-of-care test will run on the company's microfluidics-based platform, utilizing a proprietary and highly sensitive novel non-optical sensor," continued Mr. Gombrich.
The company is also pleased to announce the appointment of Thomas Umbel as President and COO. Tom comes to OncoGenesis with over 35 years of multi-discipline experience in companies ranging in size from start-ups to major global corporations.
For the past 15 years, Tom has held various senior management positions at Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostic products with an emphasis on serving the healthcare needs of women throughout the world. Tom joined Hologic through the successful sale of Direct Radiography Corp where he served as Vice President and General Manager. In 2002, Tom was promoted to Group SVP for Business Development. Amongst his most notable achievements in this role were the successful acquisitions of Cytyc Corp ($6.6 Billion) and GenProbe ($3.8 Billion).
"We are very fortunate to have someone of Tom's experience and credentials join our company," said Peter Gombrich. Adding, "Tom brings deep experience in women's health to OncoGenesis. As we expand beyond cervical screening he will be instrumental in leading the company to the next level."
"I am very pleased to be joining this exciting venture," said Umbel. "The OncoGenesis team is comprised of successful managers, scientists and engineers backed by an exceptional group of global scientific and medical advisors. I look forward to leading this team in bringing these breakthrough technologies to market."
Formerly CerMed (founded in 2008), OncoGenesis is a global company focused on the development of multiplexed biomarker-based systems that identify the presence and progression of cancer. The company's focus addresses the great, unmet need for identifying and treating cancers in women: cervical, uterine, ovarian, endometrial and breast. The initial opportunity will focus on cervical cancer screening, replacing the current 160M global pap smears performed each year.